Switching Between Duloxetine and Mirtazapine
Switching from duloxetine to mirtazapine for depression is commonly performed using a cautious cross-taper over 2 to 4 weeks, with adjustment based on tolerability. [1,2] During the switch, monitoring should address withdrawal symptoms, new adverse effects, serotonin-syndrome risk, and return or worsening of depressive symptoms. [3]
Medication Selection Algorithm
A cross-taper strategy is recommended for switching from an SNRI (duloxetine) to mirtazapine. [1,2] Key risk checks should include the following prior to and during switching: [3]
- Suicide risk and age (requires earlier follow-up after initiation of the new antidepressant). [3]
- Concomitant serotonergic medications that increase serotonin syndrome risk. [3]
- Prior antidepressant discontinuation symptoms, which increase the likelihood of withdrawal during dose reduction. [4]
Tapering Schedule for Duloxetine Discontinuation
Abrupt duloxetine discontinuation should be avoided because antidepressant withdrawal symptoms can occur. [4] For duloxetine discontinuation, dose reduction should be performed gradually over at least 1 to 2 weeks. [5,6] An example duloxetine taper from 60 mg/day is described as follows: [5]
- Reduce to 30 mg/day for several days to 1 week (consistent with stepping down prior to alternate-day dosing). [5]
- Then use 30 mg on alternate days for 4 days, then stop. [5] If withdrawal symptoms occur during taper, guideline-based approaches include returning to the previously tolerated dose and tapering more slowly with smaller decrements. [4]
Mirtazapine Initiation and Dose Titration During Cross-Taper
Mirtazapine initiation for adults is typically 15 mg to 30 mg daily, often given at night due to sedating effects early in treatment. [7,8] A cross-taper approach can use staged mirtazapine increases (example schedule used by SPS for introducing mirtazapine during cross-tapering: 15 mg daily in Week 1, 30 mg daily in Week 2, 30 mg daily in Week 3, and 45 mg daily if required in Week 4). [2] The cross-taper duration should generally be 2 to 4 weeks, with speed determined by individual tolerability. [1,2]
Common Switching Framework (Example Cross-Taper)
A cautious cross-taper over 2 to 4 weeks can be operationalized as follows: [1,2]
- Week 1: Begin mirtazapine at 15 mg (or 30 mg if clinically appropriate) while reducing duloxetine. [2,7]
- Week 2: Increase mirtazapine to 30 mg while continuing duloxetine reduction toward discontinuation. [2]
- Week 3: Continue mirtazapine at 30 mg while duloxetine is fully discontinued. [2,5,6]
- Week 4: Increase mirtazapine to 45 mg only if required for response and tolerability. [2] This framework should be individualized for dose-equivalency constraints and withdrawal risk. [3,4]
Monitoring During and After Switching
Monitoring schedule
After starting the new antidepressant, follow-up should generally occur within 2 weeks. [3] If suicide risk is present or the patient is aged 18 to 25 years, review should occur 1 week after starting the new antidepressant and again as needed, but no later than 4 weeks after initiation. [3]
Symptom targets for monitoring
Monitoring should explicitly assess the following: [3]
- Withdrawal symptoms from stopping the antidepressant, which can include psychological symptoms (e.g., irritability, anxiety, low mood, sleep disturbances, suicidal ideation, hallucinations) and physical symptoms (e.g., dizziness, headaches, “brain zaps,” unsteadiness, palpitations, tremors, gastrointestinal disturbances). [3]
- Serotonin syndrome features, which can include autonomic dysfunction, neuromuscular hyperactivity, and altered mental status. [3]
- Treatment response and relapse or worsening depression. [3]
Management of withdrawal symptoms during the switch
If more severe withdrawal symptoms occur during dose reduction, guidance supports restarting the original antidepressant at the previously effective tolerated dose and tapering more slowly with smaller decrements after symptom resolution. [4]
Target Goals of Therapy
Treatment response should be reassessed after adequate time for effect from the new antidepressant, which may take 1 to 2 weeks before benefits are felt. [3] If no benefit is seen after 4 to 6 weeks, the medication regimen should be reviewed. [3]
Common Pitfalls to Avoid
Abrupt discontinuation of duloxetine should be avoided because antidepressant withdrawal symptoms can occur after reducing or stopping antidepressants. [4,6] Cross-taper speed should not exceed what is tolerated because monitoring guidance states withdrawal symptoms should guide the speed of the switch. [3] Serotonin syndrome risk should not be ignored during antidepressant switching because concomitant or sequential antidepressant use can increase serotonin syndrome risk. [3]
Safety Triggers for Urgent Reassessment
Urgent reassessment is warranted for signs concerning for serotonin syndrome (autonomic instability, neuromuscular hyperactivity, or altered mental state) during the switch. [3] Urgent reassessment is also warranted for emergence or worsening suicidal ideation during monitoring, particularly early after starting or changing antidepressant therapy. [3,4]